These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26269021)

  • 1. [Recent progress in application of local drug delivery for preventing restenosis after peripheral arterial revascularization].
    Zhang M; Zhang F; Zhang H; Liang G
    Zhonghua Wai Ke Za Zhi; 2015 Mar; 53(3):237-40. PubMed ID: 26269021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local drug delivery to prevent restenosis.
    Seedial SM; Ghosh S; Saunders RS; Suwanabol PA; Shi X; Liu B; Kent KC
    J Vasc Surg; 2013 May; 57(5):1403-14. PubMed ID: 23601595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of various percutaneous interventions for in-stent restenosis: comprehensive network meta-analysis of randomized controlled trials.
    Sethi A; Malhotra G; Singh S; Singh PP; Khosla S
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002778. PubMed ID: 26546577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
    Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
    J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
    Vaina S; Ong AT; Serruys PW
    Minerva Cardioangiol; 2005 Oct; 53(5):341-60. PubMed ID: 16179880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on drug-eluting stents for prevention of restenosis.
    Lee CH; Tan HC; Lim YT
    Asian Cardiovasc Thorac Ann; 2006 Feb; 14(1):75-82. PubMed ID: 16432127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
    Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
    JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives of drug-eluting stents: the next revolution.
    Moses JW; Kipshidze N; Leon MB
    Am J Cardiovasc Drugs; 2002; 2(3):163-72. PubMed ID: 14727979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation.
    Herdeg C; Göhring-Frischholz K; Haase KK; Geisler T; Zürn C; Hartmann U; Wöhrle J; Nusser T; Dippon J; May AE; Gawaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):294-301. PubMed ID: 20031731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.
    Ardissino D; Cavallini C; Bramucci E; Indolfi C; Marzocchi A; Manari A; Angeloni G; Carosio G; Bonizzoni E; Colusso S; Repetto M; Merlini PA;
    JAMA; 2004 Dec; 292(22):2727-34. PubMed ID: 15585732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-eluting stents: current clinical experience.
    Grube E; Buellesfeld L
    Am J Cardiovasc Drugs; 2004; 4(6):355-60. PubMed ID: 15554720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of coronary restenosis: systemic and local approaches.
    Guerra E; Byrne RA; Kastrati A
    Expert Opin Pharmacother; 2014 Oct; 15(15):2155-71. PubMed ID: 25145263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of lesions with a high risk of stenosis. Comparative study in 300 patients of rapamycin- and Paclitaxel-eluting polymer-based stents, and bare metal stents].
    de la Torre Hernández JM; Sainz Laso F; Ruisánchez C; Zueco J; Figueroa A; Colman T
    Rev Esp Cardiol; 2005 Mar; 58(3):262-9. PubMed ID: 15766448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stents: preventing restenosis.
    Slavin L; Chhabra A; Tobis JM
    Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents in vascular intervention.
    Fattori R; Piva T
    Lancet; 2003 Jan; 361(9353):247-9. PubMed ID: 12547552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.